RxDoctor Payments Data

Sierra Bell

Acute Care · West Chester, PANPI 1417737503

Payments from drug & device makers

$1,523in general payments, 2019–2025

Across 61 payments — averaging $24.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$472
  • Boehringer Ingelheim$178
  • Amgen$178
  • E.r. Squibb & Sons, L.L.C.$134
  • Pfizer$103
  • Esperion Therapeutics, Inc.$100
  • plus $358 from 7 others

What the payments were for

  • Food & beverage$1,523100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,523 in reported general payments places this provider in the 85th percentile of 872 acute care providers in Pennsylvania.

See all acute care providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$13,947
Medicare patients
325
Services billed
392

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban75$83,626
JardianceEmpagliflozin15$17,094
EntrestoSacubitril/Valsartan11$12,877
XareltoRivaroxaban11$8,311
Metoprolol Succinate111$2,108
Ezetimibe55$1,913
Valsartan14$656
Rosuvastatin Calcium43$639
Atorvastatin Calcium38$613
Amlodipine Besylate65$532
Carvedilol17$301
Losartan Potassium21$274
Lisinopril50$262
Pravastatin Sodium17$255
Nifedipine ErNifedipine11$247

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$103$83,62675 claims
Boehringer IngelheimJardiance$178$17,09415 claims
NovartisEntresto$472$12,87711 claims
Johnson & JohnsonXarelto$18$8,31111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 872 acute care providers in Pennsylvania.

Other acute care in West Chester

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →